THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA - News), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name TcelnaTM. The product, previously known as Tovaxin®, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
